BioSpace News Archive

ATCOR Medical today announces it has entered into a partnership agreement with Datacubed Health, a leading eClinical technology company, advancing access to healthcare for everyone, everywhere.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor® in newborn infants, published in the journal Pediatric Drugs.

cystetic Medicines, Inc., a clinical-stage biotechnology company developing small molecule channels that serve as molecular prosthetics for missing or dysfunctional CFTR protein channels, announced today that the first healthy volunteer has been dosed with CM001 in a Phase 1 clinical trial.

Option Care Health, Inc. announced that it has terminated its previously announced agreement to combine with Amedisys, Inc.

BioTech Medics, Inc. is pleased to announce that the firm has made significant steps to diversify BMCS into a new dynamic and productive business.

Amyris, Inc. announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately.

Genesys Spine today announced the launch of the SIros O™ Oblique SI Fusion system.

RefleXion Medical, Inc. today announced that results of a prospective investigator-initiated clinical imaging study conducted on its X1 platform by City of Hope using positron emission tomography (PET) were presented on June 24 during an oral session at the Society of Nuclear Medicine and Medical Imaging (SNMMI) annual meeting in Chicago.

Therapeutic Solutions International (TSOI) announced today filing with the FDA for Orphan Drug Designation for its JadiCell Adult Stem Cell Product for treatment of Acute Respiratory Distress Syndrome (ARDS).

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant individuals at high risk of early-onset severe (EOS) hemolytic disease of the fetus and newborn (HDFN).